Cargando…
Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression
Vitiligo is an autoimmune disease in which melanocyte destruction causes skin depigmentation, with 49 loci known from previous GWAS. Aiming to define vitiligo subtypes, we discovered that age-of-onset is bimodal; one-third of cases have early onset (mean 10.3 years) and two-thirds later onset (mean...
Autores principales: | Jin, Ying, Roberts, Genevieve H. L., Ferrara, Tracey M., Ben, Songtao, van Geel, Nanja, Wolkerstorfer, Albert, Ezzedine, Khaled, Siebert, Janet, Neff, Charles P., Palmer, Brent E., Santorico, Stephanie A., Spritz, Richard A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344500/ https://www.ncbi.nlm.nih.gov/pubmed/30674883 http://dx.doi.org/10.1038/s41467-019-08337-4 |
Ejemplares similares
-
Autoimmunity in Segmental Vitiligo
por: Speeckaert, Reinhart, et al.
Publicado: (2020) -
Patients’ Perception of Vitiligo Severity
por: VAN GEEL, Nanja, et al.
Publicado: (2021) -
Reliability and validity of the Vitiligo Signs of Activity Score (VSAS)
por: van Geel, N., et al.
Publicado: (2020) -
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants
por: Jin, Ying, et al.
Publicado: (2016) -
Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice
por: van Geel, Nanja, et al.
Publicado: (2022)